Cargando…
Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
Non-small cell lung cancer (NSCLC) has the highest incidence of cancer-related death worldwide and a high medical need for more effective therapies. Small-molecule inhibitors of the bromodomain and extra terminal domain (BET) family such as JQ1, I-BET762 and OTX-015 are active in a wide range of dif...
Autores principales: | Klingbeil, Olaf, Lesche, Ralf, Gelato, Kathy A, Haendler, Bernard, Lejeune, Pascale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059870/ https://www.ncbi.nlm.nih.gov/pubmed/27607580 http://dx.doi.org/10.1038/cddis.2016.271 |
Ejemplares similares
-
Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition
por: Gelato, K A, et al.
Publicado: (2018) -
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010) -
Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016) -
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
por: Filippakopoulos, Panagis, et al.
Publicado: (2012)